Low molecular weight gels (LMWGs) have significant advantages in drug delivery such as high drug loading capacity, in situ delivery of drug to the lesion site, sustaining drug release with excellent bioavailability, and minimized side effects. Here, we synthesized a reactive oxygen species (ROS)-responsive gelator to prepare an injectable gel. An anticancer drug, doxorubicin hydrochloride (DOX), and a photosensitizer, Zn(II) phthalocyanine tetrasulfonic acid (ZnPCS₄), were loaded into the gel for combined chemo-photodynamic therapy. The ROS-responsive gelator was characterized by proton nuclear magnetic resonance (¹H NMR) and the morphology of gels was investigated by scanning electron microscopy (SEM). The rheological properties and destruction–recovery capability of both blank and drug-loaded gels were studied. The cytotoxicity of LMWGs against 3T3 fibroblasts and 4T1 breast cancer cells was tested. The in vitro drug release of both drugs was studied and the in vivo anticancer activities of DOX–ZnPCS₄-coloaded LMWGs were investigated in tumor-bearing mice. The results revealed that the injectable ROS-responsive DOX–ZnPCS₄-coloaded LMWGs exhibited excellent anti-tumor efficacy by a synergistic therapy.

中文翻译：

---

活性氧（ROS）响应低分子量凝胶与阿霉素和Zn（II）酞菁四磺酸共载用于化学光动力学联合治疗

低分子量凝胶（LMWGs）在药物输送中具有显着的优势，例如高载药量，将药物原位输送到病变部位，以优异的生物利用度维持药物释放并最大程度地减少了副作用。在这里，我们合成了活性氧（ROS）响应胶凝剂，以制备可注射的凝胶。将抗癌药盐酸阿霉素（DOX）和光敏剂Zn（II）酞菁四磺酸（ZnPCS ₄）装入凝胶中，以进行化学光动力疗法联合治疗。ROS反应性胶凝剂的特征在于质子核磁共振（¹1 H NMR）和凝胶的形态通过扫描电子显微镜（SEM）研究。研究了空白凝胶和载药凝胶的流变特性和破坏恢复能力。测试了LMWG对3T3成纤维细胞和4T1乳腺癌细胞的细胞毒性。在体外两种药物的药物释放进行了研究和体内DOX-ZnPCS的抗癌活性_4个-coloaded LMWGs是在荷瘤小鼠的影响。结果表明，通过协同治疗，可注射的ROS反应性DOX–ZnPCS ₄负载的LMWGs表现出优异的抗肿瘤功效。